BioCentury | Nov 7, 2020
Deals

Galapagos gains new antifibrotic mechanism through OncoArendi deal

...By Lauren Martz, Senior Editor Galapagos’ latest move to expand its early fibrosis pipeline, via a...
...the company access to a new fibrosis-blocking immune mechanism. Through the exclusive collaboration and licensing agreement, Galapagos N.V....
...million ($343 million) in development, regulatory and commercial milestones and tiered royalties up to low double-digits.Galapagos...
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...By BC Staff EMA reviewing filgotinib for ulcerative colitisGilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG...
...Pharmaceuticals Inc. Cystic Fibrosis Foundation DBV Technologies S.A. European Medicines Agency (EMA) U.S. Food and Drug Administration (FDA) Gilead Sciences Inc. Galapagos N.V. Karyopharm...
BioCentury | Oct 29, 2020
Product Development

Gilead leaning on cancer deals for growth as filgotinib’s future hangs in the balance

...most notably with ADC developer Immunomedics, for near-term growth. Filgotinib, the centerpiece of an ongoing R&D collaboration with Galapagos N.V. (Euronext:GLPG...
...TACSTD2; EGP-1) – Tumor-associated calcium signal transducer 2 Virginia Li Gilead Sciences Inc. Jyseleca, filgotinib (GLPG0634, GS-6034)Gilead Sciences Inc.Galapagos N.V....
BioCentury | Oct 13, 2020
Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients

...therapies —Jyseleca filgotinib from Gilead and Galapagos...
...are close behind. Partners Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V....
...receptor 1 Stephen Hansen Jyseleca, filgotinib (GLPG0634, GS-6034) Gilead Sciences Inc. Galapagos N.V. Janus...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...first orders this week. Paul Bonanos Jyseleca, filgotinib (GLPG0634, GS-6034) D-0502 Galapagos N.V. InventisBio...
BioCentury | Sep 12, 2020
Product Development

Galapagos gains on Phase II win for systemic sclerosis candidate

...By Virginia Li, Associate Editor Galapagos’ investors rewarded a clinical win on Friday for ziritaxestat, which...
...Detailed data will be presented at a future medical meeting.The readout is welcome news for Galapagos N.V....
...$1.1 billion in equity up front (see “Filgotinib Setback”; “Europe’s Next Big Biotech”). Despite Friday’s bump, Galapagos’...
BioCentury | Aug 21, 2020
Regulation

Data Bytes: FDA approving new drugs at rapid clip in 2020

...therapies received complete response letters from FDA: filgotinib, a JAK inhibitor from Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V....
BioCentury | Aug 19, 2020
Product Development

Filgotinib setback a blow to building franchise around Gilead-Galapagos therapy

...would be inclined to zero out in both Gilead and Galapagos valuations for the time being.” Galapagos...
...include an option for the entire Galapagos pipeline in a 10-year, $5.1 billion partnership last year. Galapagos...
...upon the U.S. approval of filgotinib (see “Gilead’s $5.1B Galapagos Deal” and “How Gilead Deal Positions Galapagos”).Poszepczynski...
BioCentury | Aug 15, 2020
Deals

Scipher tech could fatten Galapagos’ IBD pipeline

...By  Sandi Wong, Assistant Editor Galapagos’ deal with...
...company and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) will jointly validate. Galapagos...
...Decoding Drug Response from Protein Interactions”).Richard Janssen, Galapagos VP...
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

...Analyst AbbVie Inc. Allergan plc Takeda Pharmaceutical Co. Ltd. Shire plc Bristol Myers Squibb Co. Celgene Corp. Johnson & Johnson Actelion Ltd. Gilead Sciences Inc. Galapagos N.V. Arcus...
Items per page:
1 - 10 of 643
BioCentury | Nov 7, 2020
Deals

Galapagos gains new antifibrotic mechanism through OncoArendi deal

...By Lauren Martz, Senior Editor Galapagos’ latest move to expand its early fibrosis pipeline, via a...
...the company access to a new fibrosis-blocking immune mechanism. Through the exclusive collaboration and licensing agreement, Galapagos N.V....
...million ($343 million) in development, regulatory and commercial milestones and tiered royalties up to low double-digits.Galapagos...
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...By BC Staff EMA reviewing filgotinib for ulcerative colitisGilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG...
...Pharmaceuticals Inc. Cystic Fibrosis Foundation DBV Technologies S.A. European Medicines Agency (EMA) U.S. Food and Drug Administration (FDA) Gilead Sciences Inc. Galapagos N.V. Karyopharm...
BioCentury | Oct 29, 2020
Product Development

Gilead leaning on cancer deals for growth as filgotinib’s future hangs in the balance

...most notably with ADC developer Immunomedics, for near-term growth. Filgotinib, the centerpiece of an ongoing R&D collaboration with Galapagos N.V. (Euronext:GLPG...
...TACSTD2; EGP-1) – Tumor-associated calcium signal transducer 2 Virginia Li Gilead Sciences Inc. Jyseleca, filgotinib (GLPG0634, GS-6034)Gilead Sciences Inc.Galapagos N.V....
BioCentury | Oct 13, 2020
Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients

...therapies —Jyseleca filgotinib from Gilead and Galapagos...
...are close behind. Partners Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V....
...receptor 1 Stephen Hansen Jyseleca, filgotinib (GLPG0634, GS-6034) Gilead Sciences Inc. Galapagos N.V. Janus...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...first orders this week. Paul Bonanos Jyseleca, filgotinib (GLPG0634, GS-6034) D-0502 Galapagos N.V. InventisBio...
BioCentury | Sep 12, 2020
Product Development

Galapagos gains on Phase II win for systemic sclerosis candidate

...By Virginia Li, Associate Editor Galapagos’ investors rewarded a clinical win on Friday for ziritaxestat, which...
...Detailed data will be presented at a future medical meeting.The readout is welcome news for Galapagos N.V....
...$1.1 billion in equity up front (see “Filgotinib Setback”; “Europe’s Next Big Biotech”). Despite Friday’s bump, Galapagos’...
BioCentury | Aug 21, 2020
Regulation

Data Bytes: FDA approving new drugs at rapid clip in 2020

...therapies received complete response letters from FDA: filgotinib, a JAK inhibitor from Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V....
BioCentury | Aug 19, 2020
Product Development

Filgotinib setback a blow to building franchise around Gilead-Galapagos therapy

...would be inclined to zero out in both Gilead and Galapagos valuations for the time being.” Galapagos...
...include an option for the entire Galapagos pipeline in a 10-year, $5.1 billion partnership last year. Galapagos...
...upon the U.S. approval of filgotinib (see “Gilead’s $5.1B Galapagos Deal” and “How Gilead Deal Positions Galapagos”).Poszepczynski...
BioCentury | Aug 15, 2020
Deals

Scipher tech could fatten Galapagos’ IBD pipeline

...By  Sandi Wong, Assistant Editor Galapagos’ deal with...
...company and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) will jointly validate. Galapagos...
...Decoding Drug Response from Protein Interactions”).Richard Janssen, Galapagos VP...
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

...Analyst AbbVie Inc. Allergan plc Takeda Pharmaceutical Co. Ltd. Shire plc Bristol Myers Squibb Co. Celgene Corp. Johnson & Johnson Actelion Ltd. Gilead Sciences Inc. Galapagos N.V. Arcus...
Items per page:
1 - 10 of 643